Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders

25 November 2021 : Clinical Research

Giovanni Franchin^1ADEF, Nikhitha Mantri^2ABDEF, Maleeha Zahid^2BEF, Haozhe Sun^2BE, Sudharsan R. Gongati

^2BE, Diana M. Ronderos^2BE, Snigdha Gadireddy^2BE, Sridhar Chilimuri^2ABDEF*

DOI: 10.12659/MSM.934267

Med Sci Monit 2021; 27:e934267

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Description of each patient’s presenting symptoms, current therapy, follow-up period, and adverse events.

Case	Underlying rheumatological disease	Current Medications	Presenting symptoms	Infusion administered	Adverse events during infusion	Follow-up duration	Adverse events during follow-up period
1	Psoriasis	LevothyroxineVitamin B12Ibuprofen	Fatigue, body aches, sore throat, ageusia and anosmia	Bamlanivimab	None	73 days	None
2	Systemic lupus erythematosus	OmeprazoleNifedipineAmlodipineDenosumabMycophenolateCalciumVitamin DDuloxetineLosartanPioglitazoneSimvastatinMetforminPancreatic enzymes	Anosmia, ageusia, fatigue, subjective fever and cough	Bamlanivimab	None	87 days	None
3	Sjogren syndrome and Raynaud disease	AspirinMetoprololOlmesartanVitamin EMagnesium	Anosmia, ageusia, fatigue, subjective fever and cough	Casirivimab-imdevimab	None	111 days	None
4	Psoriatic arthritis	IxekizumabDulaglutideParoxetineAmlodipineBenazepril	Myalgia, subjective fever, cough, sore throat, and anosmia	Casirivimab-imdevimab	None	45 days	None

Back to the Article